Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.
The Princeton, N.J., biopharmaceutical company said the recommendation cover Augtyro as a treatment for adults with ROS1-positive advanced non-small cell lung cancer and for certain patients 12 and older with advanced solid tumors expressing a NTRK gene fusion.
The European Commission, which generally follows CHMP's advice, will now review the recommendation, with a decision expected in January.
Bristol Myers said Augtyro, if approved, has the potential to be a best-in-class treatment for patients with advanced ROS1-positive non-small cell lung cancer in the European Union.
The U.S. Food and Drug Administration last year approved Augtyro for adults with ROS1-positive non-small cell lung cancer and earlier this year gave a green light to the drug in patients with NTRK-positive solid tumors.
Bristol Myers reported Augtyro sales of $23 million for the first nine months of 2024
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.